NI 0101

Drug Profile

NI 0101

Alternative Names: NI-0101

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator NovImmune SA
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 05 Dec 2016 NovImmune and Genentech enter into an agreement for the exclusive option to license NI 0101, for the treatment of rheumatoid arthritis and other autoimmune diseases
  • 05 Dec 2016 NovImmune plans a phase II trial for Rheumatoid arthritis
  • 02 Nov 2015 The US FDA and the UK MHRA approves clinical trial application for NI 0101 in Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top